- Germany Takes a Bold Step: Bundestag Passes Bill to Legalize Cannabis
- Smokers’ Immune Genetic Feature Found to Lower Lung Cancer Risk
- Study of 27 Million People: Cardiovascular Disease Patients May Be More Prone to Cancer
- Unlocking the Mystery of Fatigue: Acetylcholine Therapy for Post-COVID-19 Syndrome
- Study Finds Closing Toilet Lid Does Not Reduce Virus Spread
- The century-old BCG vaccine may be the nemesis of stubborn liver cancer
COVID-19: Mixed vaccination may cause moderate adverse reactions
COVID-19: Mixed vaccination may cause moderate adverse reactions. New study: Mixed vaccination of different COVID-19 vaccines may cause moderate adverse reactions.
London, May 13 news, the University of Oxford in the United Kingdom released the preliminary results of a study on the 13th, showing that the mixed vaccination of subjects with the two major COVID-19 vaccines currently in use in the UK is compared with the normal two doses of the same vaccine. The occurrence of mild to moderate adverse reactions is more frequent. However, the duration of these adverse reactions is very short.
According to Oxford University, this research project uses a mixture of the COVID-19 vaccine jointly developed by Oxford University and AstraZeneca Pharmaceuticals, and the COVID-19 vaccine jointly developed by Pfizer and German Biotech.
Preliminary results show that under the premise that the two doses are given 4 weeks apart, whether it is to receive one dose of AstraZeneca vaccine first, then one dose of Pfizer vaccine, or reverse the order of the two doses, both are given the same amount as the regular two doses. Compared with vaccines, subjects have more frequent mild to moderate adverse reactions, but the duration of these adverse reactions is very short.
Matthew Snape, the lead scientist of the project and an associate professor at Oxford University, said that preliminary data analysis did not show that there are other safety concerns or signs of mixed vaccination with different vaccines, and the current analysis results at this stage are still unable to determine the immunization after mixed vaccination. Whether the response will be affected, the team hopes that more data will be available to analyze related issues in the next few months.
In addition, the team said that since the subjects in this phase of the trial are mainly people aged 50 years and above, it is also possible that adverse reactions caused by mixed vaccination have a higher chance of appearing in lower age groups. But these need more test data to verify.
This pilot project led by the University of Oxford received financial support from the British government, mainly to explore whether different types of COVID-19 vaccines can be more flexibly mixed and used. According to Oxford University, researchers have published an article in the British medical journal “The Lancet” expounding the preliminary results of the experimental data analysis.
At present, many countries in the world are facing the pressure of insufficient supply of COVID-19 vaccine, especially in low-income countries that the problem of “a dose is difficult to find” has attracted widespread attention. Most of the COVID-19 vaccines approved globally require two doses. If different vaccines can be mixed in the two vaccinations, the flexibility of vaccine supply will be greatly improved.
(source:internet, reference only)
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.